Galera Competitors

Delisted . USA . 
Stock . Galera Therapeutics
GRTXDelisted Stock  USD 2.58  0.19  6.86%   
Galera Therapeutics competes with Mereo BioPharma, Terns Pharmaceuticals, PDS Biotechnology, Inozyme Pharma, and Hookipa Pharma; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Galera Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Galera Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Galera Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Galera Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
2.582.582.58
Details
Intrinsic
Valuation
LowRealHigh
2.372.372.84
Details
Naive
Forecast
LowNextHigh
2.692.692.69
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.552.833.11
Details

Galera Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Galera Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Galera and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Galera Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
HOOK
+ 0.89
INZY
XFOR
+ 0.89
HOOK
INZY
+ 0.83
MREO
XFOR
+ 0.82
TERN
XFOR
+ 0.81
INZY
HOOK
+ 0.79
MREO
  
High negative correlations   
AMLX
- 0.76
HOOK
AMLX
- 0.73
INZY
AMLX
- 0.67
TERN
AMLX
- 0.66
XFOR
AMLX
- 0.51
MREO
AMLX
- 0.36
PDSB

Risk-Adjusted Indicators

There is a big difference between Galera Pink Sheet performing well and Galera Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Galera Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Galera Therapeutics Competitive Analysis

The better you understand Galera Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Galera Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Galera Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
GRTX MREO TERN PDSB INZY HOOK XFOR ABOS DAWN AMLX
 6.86 
 2.58 
Galera
 1.40 
 3.61 
Mereo
 1.58 
 6.24 
Terns
 1.86 
 2.19 
PDS
 0.37 
 2.71 
Inozyme
 1.61 
 2.52 
Hookipa
 11.43 
 0.39 
XFOR
 0.44 
 2.27 
Acumen
 1.53 
 13.93 
Day
 3.48 
 5.54 
Amylyx
Market Volatility
(90 Days Market Risk)
Very steady
Relatively risky
Slightly risky
Very risky
Slightly risky
Very risky
Abnormally volatile
Moderately volatile
Not too volatile
Slightly risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Weak
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Average
Above Average
Average
Average
Very High
Average
Average
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
5.02
7.92
23.59
12.34
14.54
5.48
2.39
37.21
31.45
7.96
Net Asset
26.14 M
66.5 M
268.52 M
59.39 M
200.85 M
161.34 M
147.26 M
310.12 M
376.05 M
517.45 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
-0.93
31.32
N/A
-0.83
-1.32
EBITDA
(46.69 M)
(26.06 M)
(102.56 M)
(40.08 M)
(74.81 M)
(77.34 M)
(107.52 M)
(51.61 M)
(206.06 M)
39.89 M
Current Valuation
146.68 M
485.46 M
158.55 M
56.84 M
89.27 M
(26.55 M)
10.25 M
(35.49 M)
849.02 M
147.93 M
Price To Book
29.39
7.71
1.45
3.72
2.1
0.42
1.12
0.63
2.53
1.94
Operating Margin
N/A
-37.9
N/A
N/A
N/A
-17.37
-60.21
N/A
0.32
-181.88
Retained Earnings
(437.41 M)
(419.63 M)
(332.63 M)
(144.5 M)
(285.93 M)
(369.26 M)
(477.9 M)
(222.8 M)
(458.58 M)
(304.95 M)
Current Asset
36.65 M
94 K
N/A
39.11 M
N/A
26.61 M
N/A
N/A
N/A
N/A
Beta
2.03
0.97
-0.33
1.93
1.54
0.83
0.39
0.039
-1.52
-0.7
Number Of Employees
7
33
66
25
59
151
127
51
174
384
Equity Positions Weight
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
50.03
Shares Outstanding
54.39 M
153.85 M
84.94 M
37.41 M
64.24 M
9.66 M
170.55 M
60.08 M
100.85 M
68.55 M
Cash Flow From Operations
(44.85 M)
(21.13 M)
(67.39 M)
(33.64 M)
(70.67 M)
(57.52 M)
(96.51 M)
(43.06 M)
(146.85 M)
11.92 M
Total Debt
152.3 M
5.95 M
603 K
23.85 M
46.59 M
6.56 M
58.28 M
28.49 M
408 K
4.24 M
Return On Equity
-10.63
-0.48
-0.28
-1.28
-0.79
-0.49
0.22
-0.33
-0.18
-0.84
Return On Asset
-0.59
-0.24
-0.19
-0.4
-0.36
-0.2
-0.4
-0.21
-0.25
-0.43
Number Of Shares Shorted
2.12 M
5.63 M
3.98 M
3.87 M
3.31 M
39.54 K
12.94 M
1.47 M
18.66 M
1.53 M
Book Value Per Share
-2.48
0.51
4.29
0.79
1.29
7.45
0.31
3.62
5.51
2.86
Current Liabilities
5.37 M
729 K
N/A
4.54 M
N/A
25.01 M
N/A
N/A
N/A
N/A
Total Asset
26.14 M
66.5 M
268.52 M
59.39 M
200.85 M
161.34 M
147.26 M
310.12 M
376.05 M
517.45 M
Debt To Equity
0.087
0.19
0.01
0.007
0.02
0.052
1.28
N/A
0.002
0.036
Short Ratio
1.16
6.58
3.16
10.47
10.99
1.08
8.64
6.21
14.96
0.82
Target Price
0.5
7.22
18.19
11.5
18.75
38.75
2.68
10.8
37.0
7.5
Shares Owned By Institutions
18.95
65.66
97.72
12.35
96.67
37.16
67.66
78.48
93.21
82.46
Market Capitalization
7.89 M
630.8 M
538.51 M
81.93 M
174.73 M
29.9 M
67.02 M
136.38 M
1.4 B
393.46 M
Price To Earning
-0.78
6.73
N/A
24.7
N/A
12.06
N/A
N/A
3.88
N/A
Price To Earnings To Growth
-0.02
N/A
N/A
-0.05
-0.06
-0.19
N/A
-0.23
N/A
-0.15
Price To Sales
N/A
559.3
302.64
N/A
N/A
0.57
119.05
538.78
13.78
2.0
Net Income
(59.08 M)
(29.47 M)
(90.21 M)
(42.94 M)
(71.17 M)
(81.58 M)
(101.17 M)
(52.37 M)
(188.92 M)
49.27 M
Earnings Per Share
-0.91
-0.25
-1.18
-1.17
-1.55
-3.67
-0.08
-1.38
-0.97
-3.82
Shares Owned By Insiders
36.15
1.02
0.13
3.99
0.5
21.44
1.14
11.23
17.01
14.32
Revenue
N/A
10 M
N/A
N/A
N/A
20.13 M
N/A
N/A
N/A
380.79 M
Working Capital
16.67 M
54.27 M
255.49 M
45.43 M
181.56 M
105.13 M
99.21 M
233.64 M
345.77 M
382.62 M
Cash And Equivalents
52.01 M
94.3 M
139.81 M
52.98 M
151.48 M
117.92 M
47.38 M
189.91 M
394.86 M
206.68 M
Cash Per Share
1.94
0.81
5.51
1.86
3.77
2.16
0.69
4.69
5.38
3.53
Gross Profit
N/A
936 K
1000 K
N/A
N/A
(52.97 M)
3 M
(32.36 M)
N/A
(74.21 M)
Day Typical Price
2.63
3.59
6.22
2.18
2.73
2.51
0.39
2.27
13.82
5.61
Accumulation Distribution
0.083
0.0357
0.0563
0.0448
0.0429
0.0731
0.075
0.0303
0.035
0.0484
Market Facilitation Index
0.23
0.13
0.36
0.1
0.12
0.19
0.03
0.07
0.49
0.28
Daily Balance Of Power
(0.83)
0.3846
(0.28)
0.4
(0.08)
0.2105
1.333333
0.1429
0.4286
(0.71)
Period Momentum Indicator
(0.19)
0.05
(0.10)
0.04
(0.01)
0.04
0.04
0.01
0.21
(0.20)
Rate Of Daily Change
0.93
1.01
0.98
1.02
1.0
1.02
1.11
1.0
1.02
0.97
Day Median Price
2.66
3.58
6.21
2.18
2.74
2.51
0.39
2.28
13.77
5.65
Price Action Indicator
(0.17)
0.06
(0.02)
0.03
(0.04)
0.035
0.025
N/A
0.27
(0.21)
Relative Strength Index
43.38
42.69
44.68
38.91
28.21
31.15
42.57
44.52
47.47
57.64
Coefficient Of Variation
(21,784)
(1,108)
(2,569)
(1,207)
(361.78)
(378.92)
(3,454)
(2,507)
11853.27
343.4
Mean Deviation
2.93
2.72
3.37
3.37
2.76
2.81
5.02
3.54
2.06
4.36
Jensen Alpha
(0.14)
(0.48)
(0.33)
(0.63)
(1.22)
(1.14)
(0.47)
(0.56)
(0.09)
1.48
Total Risk Alpha
(0.67)
(0.93)
(1.05)
(1.22)
(1.60)
(1.66)
(1.96)
(0.99)
(0.40)
0.6901
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(0.04)
0.2975
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
8.25
25.52
Standard Deviation
3.87
3.59
5.08
4.85
3.59
3.82
9.95
4.73
2.49
5.63
Kurtosis
0.0942
1.12
7.38
3.21
0.2819
2.58
18.13
1.67
(0.31)
1.72
Potential Upside
7.31
4.8
6.02
7.67
5.07
6.85
8.82
7.52
3.84
10.06
Treynor Ratio
(0.03)
(0.30)
(0.22)
(0.24)
(0.59)
(1.07)
(0.22)
(0.07)
0.0143
1.4
Maximum Drawdown
18.16
17.36
34.09
31.83
16.62
22.98
62.35
28.07
11.44
33.56
Variance
14.95
12.9
25.77
23.56
12.87
14.62
98.95
22.4
6.21
31.74
Market Risk Adjusted Performance
(0.02)
(0.29)
(0.21)
(0.23)
(0.58)
(1.06)
(0.21)
(0.06)
0.0243
1.41
Risk Adjusted Performance
0.0045
(0.06)
(0.02)
(0.05)
(0.20)
(0.19)
(0.01)
(0.02)
0.0134
0.2313
Skewness
0.2003
(0.78)
1.9
(0.24)
0.0928
(0.44)
(0.70)
(0.39)
(0.39)
0.3739
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
2.77
4.11
Information Ratio
(0.04)
(0.13)
(0.07)
(0.11)
(0.31)
(0.30)
(0.04)
(0.07)
(0.05)
0.2668
Value At Risk
(5.84)
(6.31)
(5.96)
(6.76)
(7.92)
(6.67)
(10.61)
(6.78)
(3.69)
(6.13)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(1.91)
(5.11)
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
2.87
5.05
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
7.66
16.89

Galera Therapeutics Competition Performance Charts

Five steps to successful analysis of Galera Therapeutics Competition

Galera Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Galera Therapeutics in relation to its competition. Galera Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Galera Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Galera Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Galera Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Galera Therapeutics position

In addition to having Galera Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Beers Thematic Idea Now

Beers
Beers Theme
Companies involved in production and distribution of domestic and international beer. The Beers theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beers Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Consideration for investing in Galera Pink Sheet

If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Stocks Directory
Find actively traded stocks across global markets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY